Review
Dermatology For The Pediatrician: Advances In Diagnosis and Treatment of Common andNot-So-Common Skin Conditions
Abstract
Abstract
Advances have been made in understanding and treating both common and raredermatologic conditions. Atopic dermatitis benefits from bathing and ceramide moisturizers. Common allergic contact dermatitis may have specific presentations. Tinea capitis is effectively treated with terbinafine. Infantile hemangiomas should betreated early in the disease course and respond well to propranolol; any white signof ulceration should be noted. Localized alopecia areata responds well to topical clobetasol, avoiding the need for intralesional injections. Topical rapamycin can be used to treat tuberous sclerosis. Further understanding of genetics will help guide pediatricians to the proper diagnosis and treatment of skin conditions.
References
- Kaynaklar 1.Laughter D, Istvan JA, Tofte SJ, Hanifin JM. The prevalen-ce of atopic dermatitis in Oregon school children. J Am AcadDermatol 2000; 43: 649–55. 2.Tamburro J. Dermatology for the pediatrician: Advances indiagnosis and treatment of common and not-so-common skinconditions. Cleve Clin J Med 2015; 82 (11 Suppl 1): S19-23. 3.Hanifin JM, Reed ML; Eczema Prevalence and Impact Wor-king Group. A population-based survey of eczema prevalen-ce in the United States. Dermatitis 2007; 18: 82–91. 4.Ruzicka T. Atopic eczema between rationality and irrationa-lity. Arch Dermatol 1998; 134: 1462–69. 5.Kondo H, Ichikawa Y, Imokawa G. Percutaneous sensitiza-tion through barrier-disrupted skin elicits a TH2-dominant cyto-kine response. Eur J Immunol 1998; 28: 769–79. 6.Hon KL, Leung AK, Barankin B. Barrier repair therapy in ato-pic dermatitis: an overview. Am J Clin Dermatol 2013; 14: 389–99. 7.Halken S. Prevention of allergic disease in childhood: clini-cal and epidemiological aspects of primary and secondary al-lergy prevention. Pediatr Allergy Immunol 2004; 15 (Suppl16): 4–5, 9–32. 8.Marini A, Agosti M, Motta G, Mosca F. Effects of a dietaryand environmental prevention program on the incidence of al-lergic symptoms in high atopic risk infants: three years’ fol-low-up. Acta Paediatr Suppl 1996; 414: 1–21. 9.Admani S, Jacob SE. Allergic contact dermatitis in children:review of the past decade. Curr Allergy Asthma Rep 2014; 14:421. 10.Holme SA, Stone NM, Mills CM. Toilet seat contact derma-titis. Pediatr Dermatol 2005; 22: 344–45. 11.Heilig S, Adams DR, Zaenglein AL. Persistent allergic con-tact dermatitis to plastic toilet seats. Pediatr Dermatol 2011;28: 587–90. 12.Litvinov IV, Sugathan P, Cohen BA. Recognizing and treatingtoilet-seat contact dermatitis in children. Pediatrics 2010; 125:e419–e422. 13.Castanedo-Tardana MP, Zug KA. Methylisothiazolinone.Dermatitis 2013; 24: 2–6. 14.Ghali FE. “Car seat dermatitis”: a newly described form ofcontact dermatitis. Pediatr Dermatol 2011; 28: 321–26. 15.Herro E, Jacob SE. p-tert-Butylphenol formaldehyde resin andits impact on children. Dermatitis 2012; 23: 86–88. 16.Malajian D, Belsito DV. Cutaneous delayed-type hypersen-sitivity in patients with atopic dermatitis. J Am Acad Derma-tol 2013; 69: 232–37. 17.Foster KW, Ghannoum MA, Elewski BE. Epidemiologic sur-veillance of cutaneous fungal infection in the United States from1999 to 2002. J Am Acad Dermatol 2004; 50: 748–52. 18.Gupta AK, Drummond-Main C. Meta-analysis of randomized,controlled trials comparing particular doses of griseofulvinand terbinafine for the treatment of tinea capitis. Pediatr Der-matol 2013; 30: 1–6. 19.Zhang L, Mai HM, Zheng J, et al. Propranolol inhibits angio-genesis via down-regulating the expression of vascular endot-helial growth factor in hemangioma derived stem cell. Int JClin Exp Pathol 2013; 7: 48–55. 20.Drolet BA, Frommelt PC, Chamlin SL, et al. Initiation and useof propranolol for infantile hemangioma: report of a consen-sus conference. Pediatrics 2013; 131: 128–40. 21.Tollefson MM, Frieden IJ. Early growth of infantile heman-giomas: what parents’ photographs tell us. Pediatrics 2012;130: e314–e320. 22.Maguiness SM, Hoffman WY, McCalmont TH, Frieden IJ.Early white discoloration of infantile hemangioma: a sign ofimpending ulceration. Arch Dermatol 2010; 146: 1235–39. 23.Lenane P, Macarthur C, Parkin PC, et al. Clobetasol propio-nate, 0.05%, vs hydrocortisone, 1%, for alopecia areata inchildren: a randomized clinical trial. JAMA Dermatol 2014;150: 47–50. 24.Lim YH, Ovejero D, Sugarman JS, et al. Multilineage soma-tic activating mutations in HRAS and NRAS cause mosaic cu-taneous and skeletal lesions, elevated FGF23 and hypophosp-hatemia. Hum Mol Genet 2014; 23: 397–407. 25.Koenig MK, Hebert AA, Roberson J, et al. Topical rapamy-cin therapy to alleviate the cutaneous manifestations of tube-rous sclerosis complex: a double-blind, randomized, control-led trial to evaluate the safety and efficacy of topically app-lied rapamycin. Drugs R D 2012; 12: 121–26.
Pediyatristler İçin Dermatoloji: Sık ve Nadir Gözlenen Deri Hastalıklarında Tanı ve Tedavide Gelişmeler
Abstract
Öz
Sık ve nadir gözlenen dermatolojik durumların tedavi ve anlaşılmasında ilerlemeler olmaktadır. Atopik dermatitli çocuklar seramid nemlendiriciler ve banyolardan fayda görmektedir. Sık gözlenen alerjik kontakt dermatitli çocuklar spesifik prezantasyonlarla başvurabilmektedir. Tinea kapiti terbinafinle etkili bir şekilde tedavi edilmektedir. İnfantil hemanjiyomalar erken evrede tedavi edilmeli ve propranolol tedavisine iyi yanıt verebilmekte iken, herhangi bir ülserasyon belirtisi olan beyazlaşmalar not edilmelidir. Lokalize alopesi areata topikal klobetazole yanıt verirken, intralezyonel enjeksiyonlardan kaçınmak gerekir. Topikal rapamisin tüberoz sklerozis tedavisinde kullanılabilmektedir. Pediyatristlerin deri hastalığı tanı ve tedavisi içingenetik tabloyu anlaması da gerekebilmektedir.
Keywords
References
- Kaynaklar 1.Laughter D, Istvan JA, Tofte SJ, Hanifin JM. The prevalen-ce of atopic dermatitis in Oregon school children. J Am AcadDermatol 2000; 43: 649–55. 2.Tamburro J. Dermatology for the pediatrician: Advances indiagnosis and treatment of common and not-so-common skinconditions. Cleve Clin J Med 2015; 82 (11 Suppl 1): S19-23. 3.Hanifin JM, Reed ML; Eczema Prevalence and Impact Wor-king Group. A population-based survey of eczema prevalen-ce in the United States. Dermatitis 2007; 18: 82–91. 4.Ruzicka T. Atopic eczema between rationality and irrationa-lity. Arch Dermatol 1998; 134: 1462–69. 5.Kondo H, Ichikawa Y, Imokawa G. Percutaneous sensitiza-tion through barrier-disrupted skin elicits a TH2-dominant cyto-kine response. Eur J Immunol 1998; 28: 769–79. 6.Hon KL, Leung AK, Barankin B. Barrier repair therapy in ato-pic dermatitis: an overview. Am J Clin Dermatol 2013; 14: 389–99. 7.Halken S. Prevention of allergic disease in childhood: clini-cal and epidemiological aspects of primary and secondary al-lergy prevention. Pediatr Allergy Immunol 2004; 15 (Suppl16): 4–5, 9–32. 8.Marini A, Agosti M, Motta G, Mosca F. Effects of a dietaryand environmental prevention program on the incidence of al-lergic symptoms in high atopic risk infants: three years’ fol-low-up. Acta Paediatr Suppl 1996; 414: 1–21. 9.Admani S, Jacob SE. Allergic contact dermatitis in children:review of the past decade. Curr Allergy Asthma Rep 2014; 14:421. 10.Holme SA, Stone NM, Mills CM. Toilet seat contact derma-titis. Pediatr Dermatol 2005; 22: 344–45. 11.Heilig S, Adams DR, Zaenglein AL. Persistent allergic con-tact dermatitis to plastic toilet seats. Pediatr Dermatol 2011;28: 587–90. 12.Litvinov IV, Sugathan P, Cohen BA. Recognizing and treatingtoilet-seat contact dermatitis in children. Pediatrics 2010; 125:e419–e422. 13.Castanedo-Tardana MP, Zug KA. Methylisothiazolinone.Dermatitis 2013; 24: 2–6. 14.Ghali FE. “Car seat dermatitis”: a newly described form ofcontact dermatitis. Pediatr Dermatol 2011; 28: 321–26. 15.Herro E, Jacob SE. p-tert-Butylphenol formaldehyde resin andits impact on children. Dermatitis 2012; 23: 86–88. 16.Malajian D, Belsito DV. Cutaneous delayed-type hypersen-sitivity in patients with atopic dermatitis. J Am Acad Derma-tol 2013; 69: 232–37. 17.Foster KW, Ghannoum MA, Elewski BE. Epidemiologic sur-veillance of cutaneous fungal infection in the United States from1999 to 2002. J Am Acad Dermatol 2004; 50: 748–52. 18.Gupta AK, Drummond-Main C. Meta-analysis of randomized,controlled trials comparing particular doses of griseofulvinand terbinafine for the treatment of tinea capitis. Pediatr Der-matol 2013; 30: 1–6. 19.Zhang L, Mai HM, Zheng J, et al. Propranolol inhibits angio-genesis via down-regulating the expression of vascular endot-helial growth factor in hemangioma derived stem cell. Int JClin Exp Pathol 2013; 7: 48–55. 20.Drolet BA, Frommelt PC, Chamlin SL, et al. Initiation and useof propranolol for infantile hemangioma: report of a consen-sus conference. Pediatrics 2013; 131: 128–40. 21.Tollefson MM, Frieden IJ. Early growth of infantile heman-giomas: what parents’ photographs tell us. Pediatrics 2012;130: e314–e320. 22.Maguiness SM, Hoffman WY, McCalmont TH, Frieden IJ.Early white discoloration of infantile hemangioma: a sign ofimpending ulceration. Arch Dermatol 2010; 146: 1235–39. 23.Lenane P, Macarthur C, Parkin PC, et al. Clobetasol propio-nate, 0.05%, vs hydrocortisone, 1%, for alopecia areata inchildren: a randomized clinical trial. JAMA Dermatol 2014;150: 47–50. 24.Lim YH, Ovejero D, Sugarman JS, et al. Multilineage soma-tic activating mutations in HRAS and NRAS cause mosaic cu-taneous and skeletal lesions, elevated FGF23 and hypophosp-hatemia. Hum Mol Genet 2014; 23: 397–407. 25.Koenig MK, Hebert AA, Roberson J, et al. Topical rapamy-cin therapy to alleviate the cutaneous manifestations of tube-rous sclerosis complex: a double-blind, randomized, control-led trial to evaluate the safety and efficacy of topically app-lied rapamycin. Drugs R D 2012; 12: 121–26.
There are 1 citations in total.
Details
| Primary Language | Turkish |
|---|---|
| Journal Section | makale |
| Authors | |
| Publication Date | November 15, 2018 |
| Published in Issue | Year 2018 Volume: 10 Issue: 6 |
